Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Viking Therapeutics (VKTX)
NASDAQ:VKTX
VKTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$28.64 - $99.41
Previous CloseN/A
Volume7.75M
Average Volume (3M)4.26M
Market Cap
$3.26B
Enterprise Value$3.58B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta3.05
Next Earnings
Apr 23, 2025EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.01
Shares Outstanding111,436,386
10 Day Avg. Volume5,007,767
30 Day Avg. Volume4,263,133
Standard Deviation0.38
R-Squared0.02
Alpha0.06
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-37.10
P/FCF Ratio0.00
Enterprise Value/Market Cap1.10
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-12.26K
Enterprise Value/Ebitda-26.74
Forecast
1Y Price Target
$101.14Price Target Upside219.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
---
Bulls Say, Bears Say
Bulls Say
Clinical SuccessViking made significant progress in advancing its obesity franchise, achieving clinical successes with both the subcutaneous and oral formulations of VK2735.
Market OpportunityViking Therapeutics is estimated to capture a 5% market share in the U.S. obesity market, which is projected to reach a size of $75 billion.
Regulatory ProgressThe upcoming FDA meeting is expected to provide clarity on the roadmap for a Phase III registration program, which could unlock significant value for Viking Therapeutics.
Bears Say
Data RequirementsWe require longer-term data in more patients before becoming comfortable, given the high discontinuation rate associated with the class.
Market CompetitionThe market opportunity for Viking may have shifted due to the evolving commercial and reimbursement landscape.
Revenue EstimatesThe 12-month price target for Viking has been lowered to $70 from $120 due to updated revenue estimates primarily because of the evolving GLP-1 market.
---
Ownership Overview
2.79% Insiders
28.15% Mutual Funds
11.61% Other Institutional Investors
43.22% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VKTX FAQ
What was Viking Therapeutics’s price range in the past 12 months?
Viking Therapeutics lowest stock price was $28.64 and its highest was $99.41 in the past 12 months.
What is Viking Therapeutics’s market cap?
Viking Therapeutics’s market cap is $3.26B.
When is Viking Therapeutics’s upcoming earnings report date?
Viking Therapeutics’s upcoming earnings report date is Apr 23, 2025 which is in 61 days.
How were Viking Therapeutics’s earnings last quarter?
Viking Therapeutics released its earnings results on Feb 05, 2025. The company reported -$0.32 earnings per share for the quarter, missing the consensus estimate of -$0.276 by -$0.044.
Is Viking Therapeutics overvalued?
According to Wall Street analysts Viking Therapeutics’s price is currently Undervalued.
Does Viking Therapeutics pay dividends?
Viking Therapeutics does not currently pay dividends.
What is Viking Therapeutics’s EPS estimate?
Viking Therapeutics’s EPS estimate is -0.33.
How many shares outstanding does Viking Therapeutics have?
Viking Therapeutics has 111,436,386 shares outstanding.
What happened to Viking Therapeutics’s price movement after its last earnings report?
Viking Therapeutics reported an EPS of -$0.32 in its last earnings report, missing expectations of -$0.276. Following the earnings report the stock price went down -6.09%.
Which hedge fund is a major shareholder of Viking Therapeutics?
Currently, no hedge funds are holding shares in VKTX
---
Viking Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$101.14 (219.76% Upside)
$101.14 (219.76% Upside)
Blogger Sentiment
Bullish
VKTX Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $12.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 2.1%
Last 30 Days ▲ 2.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-10.80%
12-Months-Change
Fundamentals
Return on Equity
-10.88%
Trailing 12-Months
Asset Growth
146.50%
Trailing 12-Months
Company Description
Viking Therapeutics
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for patients suffering from metabolic and endocrine disorders. The company's clinical program VK5211, treats patients recovering from non-elective hip fracture surgery. It also specializes in development of VK2809 and VK0214. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.
---
VKTX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong focus on successful clinical trial results and a solid financial position, despite increased expenses and net loss. The company is advancing its lead programs with significant progress in pipeline development.Read More>---
VKTX Stock 12 Month Forecast
Average Price Target
$101.14
▲(219.76% Upside)
Technical Analysis
Neurocrine
―
Altimmune
―
Madrigal Pharmaceuticals
―
Portage Biotech Inc
―
Akero Therapeutics
―
Best Analysts Covering VKTX
1 Year
1 Year Success Rate
12/19 ratings generated profit
1 Year Average Return
+168.93%
reiterated a buy rating 15 days ago
Copying Naz Rahman's trades and holding each position for 1 Year would result in 63.16% of your transactions generating a profit, with an average return of +168.93% per trade.
---